Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: July 26, 2005
Last updated: June 17, 2012
Last verified: January 2009

RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving cetuximab together with radiation therapy may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving cetuximab together with radiation therapy works in treating patients with stage III non-small cell lung cancer.

Condition Intervention Phase
Lung Cancer
Biological: cetuximab
Radiation: radiation therapy
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: Cetuximab (C225) and Radiation in Elderly and /or Poor Performance Status Patients With Locally Advanced Non-Small Cell Lung Cancer: A Phase II Study to Evaluate Survival and Toxicity

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • 11-month survival rate [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Survival time [ Designated as safety issue: No ]
  • Time to disease progression [ Designated as safety issue: No ]
  • Tumor response (complete and partial) [ Designated as safety issue: No ]
  • Duration of response [ Designated as safety issue: No ]
  • Time to treatment failure [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: January 2006
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Detailed Description:



  • Determine the 11 month survival rate in older and/or poor performance status patients with stage IIIA or stage IIIB non-small cell lung cancer treated with cetuximab and radiotherapy.


  • Determine the tumor response rate, overall survival, and time to disease progression in patients treated with this regimen.
  • Determine the toxicity of this regimen in these patients.
  • Determine whether fear of death is less severe in the oldest of patients treated with this regimen.
  • Determine whether fear of death predicts survival of patients treated with this regimen.

OUTLINE: This is a multicenter study.

Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, and 43. Beginning on day 8, patients receive concurrent radiotherapy once daily on days 8-12, 15-19, 22-26, 29-33, 36-40, and 43-47. Treatment continues in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed within 1 week, at 1 and 4 months, and then every 3 months for up to 3 years.

PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study within 20 months


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)

    • Stage IIIA or IIIB disease
  • Must be a candidate for curative radiotherapy
  • Not a candidate for other concurrent chemotherapy and radiotherapy
  • No surgical treatment available
  • No pleural effusion suspected or proven to be malignant
  • No stage IV disease by bone scan or positron emission tomography scan, CT scan or MRI of the brain, and CT scan of the chest within the past 30 days



  • 18 and over

Performance status

  • ECOG 0-2 (age ≥ 65 years)
  • ECOG 2 (age 18 to 64 years)

Life expectancy

  • At least 12 weeks


  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 9 g/dL


  • Bilirubin ≤ 2 times upper limit of normal (ULN)
  • AST ≤ 3 times ULN


  • Creatinine ≤ 1.5 times ULN


  • FEV_1 ≥ 1 L
  • No idiopathic pulmonary fibrosis


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Magnesium normal
  • No uncontrolled infection
  • No other severe underlying disease that would preclude study entry
  • No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or noninvasive carcinoma
  • No major psychiatric illness that would preclude study participation


Biologic therapy

  • Not specified


  • See Disease Characteristics
  • No prior chemotherapy for NSCLC

Endocrine therapy

  • Not specified


  • No prior therapeutic radiotherapy to the chest
  • No concurrent intensity modulated radiotherapy


  • Not specified


  • No prior epidermal growth factor receptor inhibitors
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00124618

  Show 175 Study Locations
Sponsors and Collaborators
North Central Cancer Treatment Group
Study Chair: Aminah Jatoi, MD Mayo Clinic
Investigator: Steven E. Schild, MD Mayo Clinic
Investigator: George T. Henning, MD Saint Joseph Mercy Cancer Center
  More Information

Additional Information:
Responsible Party: Jan C. Buckner, North Central Cancer Treatment Group Identifier: NCT00124618     History of Changes
Other Study ID Numbers: CDR0000435991, NCCTG-N0422
Study First Received: July 26, 2005
Last Updated: June 17, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by National Cancer Institute (NCI):
stage IIIA non-small cell lung cancer
stage IIIB non-small cell lung cancer

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses processed this record on March 01, 2015